Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. Read Our Latest […]
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. Read Our Latest […]
